Clinical Trials · global
Lower-dose CagriSema delivers about 20% weight loss, with Phase 3 trial adding evidence on dose options
Two lower doses both outperformed placebo in a 68-week trial, but similar weight-loss figures do not mean equal efficacy, nor do they establish that reducing the dose improves tolerability.
For weight-loss medications intended for long-term use, the question is not only how much weight they can reduce, but also whether different doses can offer suitable treatment options. The REDEFINE 9 trial, announced by Novo Nordisk on November 14, adds evidence on lower doses of the investigational combination drug CagriSema: both doses produced substantial weight loss after 68 weeks. However, these results are not sufficient to determine which dose is better or whether lower doses are easier to tolerate.
CagriSema combines the long-acting amylin analogue cagrilintide with the GLP-1 receptor agonist semaglutide and is administered once weekly by subcutaneous injection. Previous Phase 3 research evaluated a combination containing 2.4 mg of each component; this trial tested 1.7 mg of each and 1.0 mg of each. The results were presented at the ObesityWeek annual meeting and simultaneously published in The Lancet Diabetes & Endocrinology. The study was funded by Novo Nordisk.
This Phase 3b randomized trial was conducted at 24 sites in Canada, France, Germany, the United Kingdom and the United States, enrolling 309 adults without diabetes. Participants had to meet the criteria for obesity, or have overweight and at least one obesity-related complication; all groups received dietary and physical activity counseling. Overall, 94% completed the study, while 82% were still receiving trial treatment at week 68. These two measures represent different things.
Under a statistical estimate assuming that all participants continued treatment as planned, mean body weight reductions were 20.7% in the group receiving 1.7 mg of each component and 21.0% in the group receiving 1.0 mg of each, compared with 2.0% in the pooled placebo group; p values for both comparisons were less than 0.0001. When treatment discontinuation or the use of other rescue weight-loss interventions was taken into account, estimated reductions were 19.4% and 18.6% in the two active-treatment groups, compared with 4.6% in the placebo group. These two sets of figures answer different questions and must be interpreted alongside the assumptions underlying the estimates.
Beyond body weight, a presentation summarizing the paper provided by the company showed that, under the assumption of continued treatment, waist circumference decreased by 17.2 and 17.5 cm in the two active-treatment groups, respectively, compared with 3.6 cm in the placebo group. However, the slightly better figures for some measures in the group receiving 1.0 mg of each component do not support the inference that lower doses work better: the study compared each dose with placebo separately and was not designed to directly determine differences between the two effective doses, nor did it have sufficient statistical power to establish their equivalence.
Tolerability remains an important consideration in dose selection. Adverse events were reported by 99%, 95% and 91% of participants in the groups receiving 1.7 mg of each component, 1.0 mg of each component and placebo, respectively. Most were mild to moderate and predominantly involved gastrointestinal symptoms. The nausea rates listed in the presentation were 66%, 62% and 26%, respectively; no deaths were reported in the study. Not all adverse events are caused by the drug, but these results also serve as a reminder that lower doses may still be associated with substantial discomfort.
The conclusion supported by REDEFINE 9 is that both lower doses can produce greater weight loss than placebo in the specific population studied, providing evidence to inform subsequent dosing plans. It did not directly compare these doses with the combination containing 2.4 mg of each component, nor can it answer whether results can be maintained after treatment stops or what the benefits and risks of use over many years may be. According to the company's announcement, CagriSema remains an investigational drug that has not been approved in the United States; regulatory requirements and long-term data gaps still need to be addressed before clinical trial evidence on dosing can translate into actual prescribing choices.